Drug Information

Drug (ID: DG01835) and It's Reported Resistant Information

• Name: Artenimol
• Synonyms: Alpha-Dihydroartemisinin; Dihydroartemisinin; Artenimol; 81496-81-3; UNII-X0UIV26ABX; X0UIV26ABX; 71939-50-9; 123930-80-3; (1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol; Dihydroartemisinin (DHA); (1S,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol; CHEMBL511326; SCHEMBL18744731; CHEBI:168754; MFCD00236467; s2290; ZINC15449189; AKOS022168199; CCG-267307; NSC 758682; NCGC00346590-02; N1713; 496D813; Q-100792; Q27293233; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3,-j)-1,2-benzodioxepin-10-ol
• Indication:
  In total 1 Indication(s)
  Malaria [ICD-11: 1F45]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Hepatic fibrosis/cirrhosis [ICD-11: DB93]; [1]
• Target: Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A); NOUNIPROTAC; [1]
• IsoSMILES: C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
• InChI: InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12-,13-,14-,15-/m1/s1
• InChIKey: BJDCWCLMFKKGEE-KDTBHNEXSA-N
• PubChem CID: 11358077
• DrugBank ID: DB11638

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-13: Digestive system diseases

Hepatic fibrosis/cirrhosis [ICD-11: DB93]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: H19, imprinted maternally expressed transcript (H19) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Hepatic fibrosis [ICD-11: DB93.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HSC cells; N.A.; .; N.A.
• Experiment for Molecule Alteration: Knockdown assay
• Mechanism Description: LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signals.

References

• Ref 1: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.